The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

Data from the Phase 3 STELLAR trial, which tested 323 participants with PAH over six months, supported the therapy’s approval ...

On Sunday September 23, the flagship Forbes Under 30 Summit kicked off in Cincinnati, Ohio, bringing together the brightest ...

RAHWAY, N.J., September 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s ...